On December 1^st, the Listed Company Roadshow of the 2024 China BioMed Innovation and Investment Conference (CBIIC) was successfully held at the Guangzhou Baiyun International Conference Center. William Sun, Healthcare Industry Head at Citi China Commercial Bank, served as the moderator. This roadshow gathered many leading enterprises in the biopharmaceutical field, with 17 innovative companies listed on different capital markets including SZSE, HKEX, SSE STAR Market, and Nasdaq participating in the roadshow to explore industry development trends and chart the industry’s development blueprint together.

William Sun

A total of 17 speakers from Boan Biotech, CStone Pharmaceuticals, Frontier Biotechnologies, InnoCare Pharma, Biocytogen Pharmaceuticals, HUTCHMED, BeiGene, Ascentage Pharma, Chipscreen Biosciences, Betta Pharmaceuticals, Harbour BioMed, Haisco Pharmaceutical, 3SBIO, Laekna, Mindray Bio-medical Electronics, HighTide Therapeutics,  and Amoy Diagnostics delivered engaging presentations, providing comprehensive demonstrations and detailed explanations about their company development history, team building, product pipeline and latest R&D progress, and global development strategies, offering attending investors and guests a feast.

First row: Jiang Hua, Yang Jianxin, Xie Dong;
Second row: Fu Xin, Guo Chaoshe, Wu Jiajun;
Third row: Shen Zhirong, Wen Dingzhou, Shan Song;
Fourth row: Ding Shizhe, Zhang Hanwen, Lin Hongjun;
Fifth row: He Xiang, Wu Qiongyuan, Huang Xianyin;
Sixth row: Han Dong, Chen Xiaoyun

The Listed Company Roadshow of CBIIC has been successfully held for nine consecutive years, witnessing the rapid development of China’s innovative pharmaceutical industry and the catalytic role of capital market opening policies in pharmaceutical industry development. The successful building of this platform has not only become a window for examining cutting-edge innovations in the biopharmaceutical field and discovering investment opportunities but has also greatly promoted exchange and cooperation among various entities within the industry, stimulating industrial vitality and creativity. Looking ahead, with the flourishing development of the biopharmaceutical industry, we believe that more disruptive innovations will emerge, contributing more significantly to the advancement of human health and well-being.

Roadshow